Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Condition: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Pembrolizumab; Drug: IO102-103 Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; IO Biotech; Merck Sharp & Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | Neoadjuvant Therapy | Research | Skin Cancer | Squamous Cell Carcinoma